Patents Assigned to Optimer Pharmaceuticals, Inc.
-
Patent number: 8044030Abstract: The invention encompasses an active metabolite of the 18-membered macrocyclic antimicrobial agents, specifically, a metabolite of tiacumicin B and in certain embodiments, R-Tiacumicin B or and its related compounds. In particular, the invention encompasses a compound that acts as a potent antibiotic agent for the treatment of bacterial infections, specifically GI infections caused by toxin producing strains of Clostridium difficile (C. difficile) and Clostridium perfringens (C. perfringens).Type: GrantFiled: November 28, 2008Date of Patent: October 25, 2011Assignee: Optimer Pharmaceuticals, Inc.Inventors: Yoshi Ichikawa, Yu-Hung Chiu, Youe-Kong Shue, Farah Kondori Babakhani
-
Patent number: 8012943Abstract: Described herein are novel macrolides, the preparation of novel macrolides, the use of novel macrolides for preventing, treating, or ameliorating various conditions, and the use of novel macrolides as antibacterial agents.Type: GrantFiled: April 27, 2009Date of Patent: September 6, 2011Assignee: Optimer Pharmaceuticals, Inc.Inventors: Jonathan Duffield, Chan-Kou Hwang, Yoshitaka Ichikawa, Youe-Kong Shue
-
Patent number: 7906489Abstract: The present invention relates generally to the 18-membered macrocyclic antimicrobial agents called Tiacumicins, specifically, OPT-80 (which is composed almost entirely of the R-Tiacumicin B), pharmaceutical compositions comprising OPT-80, and methods using OPT-80. In particular, this compound is a potent drug for the treatment of bacterial infections, specifically C. difficile infections.Type: GrantFiled: July 31, 2007Date of Patent: March 15, 2011Assignee: Optimer Pharmaceuticals, Inc.Inventors: Youe-Kong Shue, Chan-Kou Hwang, Yu-Hung Chiu, Alex Romero, Farah Babakhani, Pamela Sears, Franklin Okumu
-
Patent number: 7863249Abstract: The invention relates to novel forms of compounds displaying broad spectrum antibiotic activity, especially crystalline polymorphic forms and amorphous forms of such compounds, compositions comprising such crystalline polymorphic forms and amorphous forms of such compounds, processes for manufacture and use thereof. The compounds and compositions of the invention are useful in the pharmaceutical industry, for example, in the treatment or prevention of diseases or disorders associated with the use of antibiotics, chemotherapies, or antiviral therapies, including, but not limited to, colitis, for example, pseudo-membranous colitis; antibiotic associated diarrhea; and infections due to Clostridium difficile (“C. difficile”), Clostridium perfringens (“C. perfringens”), Staphylococcus species, for example, methicillin-resistant Staphylococcus, or Enterococcus including Vancomycin-resistant enterococci.Type: GrantFiled: April 11, 2008Date of Patent: January 4, 2011Assignee: Optimer Pharmaceuticals, Inc.Inventors: Yu-Hung Chiu, Tessie Mary Che, Alex Romero, Yoshi Ichikawa, Youe-Kong Shue
-
Publication number: 20100035833Abstract: The invention encompasses an active metabolite of the 18-membered macrocyclic antimicrobial agents, specifically, a metabolite of tiacumicin B and in certain embodiments, R-Tiacumicin B or and its related compounds. In particular, the invention encompasses a compound that acts as a potent antibiotic agent for the treatment of bacterial infections, specifically GI infections caused by toxin producing strains of Clostridium difficile (C. difficile) and Clostridium perfringens (C. perfringens).Type: ApplicationFiled: November 28, 2008Publication date: February 11, 2010Applicant: OPTIMER PHARMACEUTICALS, INC.Inventors: Yoshi Ichikawa, Yu-Hung Chiu, Youe-Kong Shue, Farah Kondori Babakhani
-
Patent number: 7601695Abstract: Described herein are novel macrolides, the preparation of novel macrolides, to the use of novel macrolides for preventing, treating, or ameliorating various conditions, and the use of novel macrolides as antibacterial agents.Type: GrantFiled: March 5, 2004Date of Patent: October 13, 2009Assignee: Optimer Pharmaceuticals, Inc.Inventors: Chang-Hsing Liang, Jonathan Duffield, Alex Romero, Yu-Hung Chiu, David Rabuka, Sulan Yao, Steve Sucheck, Kenneth Marby, Youe-kong Shue, Yoshi Ichikawa, Chan-Kou Hwang
-
Publication number: 20090247732Abstract: The present invention relates to novel glycopeptides having improved pharmacokinetic properties, improved stability, methods of preparing said novel glycopeptides, and methods to use said novel glycopeptides.Type: ApplicationFiled: November 1, 2004Publication date: October 1, 2009Applicant: Optimer Pharmaceuticals, Inc.Inventors: Jonathan Duffield, Kenneth Marby, Sean O'Hare, Chan-Kou Hwang, Yoshitaka Ichikawa
-
Publication number: 20090163428Abstract: The invention relates to novel forms of compounds displaying broad spectrum antibiotic activity, especially crystalline polymorphic forms and amorphous forms of such compounds, compositions comprising such crystalline polymorphic forms and amorphous forms of such compounds, processes for manufacture and use thereof. The compounds and compositions of the invention are useful in the pharmaceutical industry, for example, in the treatment or prevention of diseases or disorders associated with the use of antibiotics, chemotherapies, or antiviral therapies, including, but not limited to, colitis, for example, pseudo-membranous colitis; antibiotic associated diarrhea; and infections due to Clostridium difficile (“C. difficile”), Clostridium perfringens (“C. perfringens”), Staphylococcus species, for example, methicillin-resistant Staphylococcus, or Enterococcus including Vancomycin-resistant enterococci.Type: ApplicationFiled: March 4, 2009Publication date: June 25, 2009Applicant: OPTIMER PHARMACEUTICALS, INC.Inventors: Yu-Hung CHIU, Tessie Mary Che, Alex Romero, Yoshi Ichikawa, Youe-Kong Shue
-
Patent number: 7507564Abstract: Methods, processes and materials for the production and recovery of Tiacumicins produced by culturing a microorganism belonging to the species Dactylosporangium aurantiacum subspecies hamdenensis having the ability to produce and accumulate one or more Tiacumicin in a nutrient medium comprising a carbon source, a nitrogen source, trace elements such as inorganic salts, and an adsorbent, wherein said nitrogen source comprises fish powder, and wherein said Tiacumicin is produced in a yield greater than about 50 mg/L broth.Type: GrantFiled: July 15, 2003Date of Patent: March 24, 2009Assignee: Optimer Pharmaceuticals, Inc.Inventors: Youe-Kong Shue, Chi-Jen Frank Du, Ming-Hsi Chiou, Mei-Chiao Wu, Yuan-Ting Chen, Franklin W. Okumu, Jonathan James Duffield
-
Patent number: 7414885Abstract: A ferromagnetic memory cell is disclosed. The cell includes a bit (10), made of a ferromagnetic material, having a remnant polarity. The cell also includes a read drive line (20) coupled to a first portion of the bit (10), to feed a current into the bit (10). A sense conductor (30) is coupled to a second portion of the bit (10), to receive the current from the bit (10). The current conducted through the bit (10) is responsive to the polarity of the bit (10). A method is also disclosed for determining the magnetic polarity of a ferromagnetic bit (10). In this method, a bit (10) is provided that is made of ferromagnetic material and has a remnant polarity. An input current (50) is fed into the bit (10) through a read drive line (20) coupled to a first portion of the bit (10). An output current (60) is received from the bit (10) through a sense conductor (30) coupled to a second portion of the bit (10). The current conducted through the bit (10) is responsive to the polarity of the bit (10).Type: GrantFiled: December 26, 2006Date of Patent: August 19, 2008Assignee: Optimer Pharmaceuticals, Inc.Inventor: Richard M. Lienau
-
Publication number: 20080194497Abstract: The invention relates to novel forms of compounds displaying broad spectrum antibiotic activity, especially crystalline polymorphic forms and amorphous forms of such compounds, compositions comprising such crystalline polymorphic forms and amorphous forms of such compounds, processes for manufacture and use thereof. The compounds and compositions of the invention are useful in the pharmaceutical industry, for example, in the treatment or prevention of diseases or disorders associated with the use of antibiotics, chemotherapies, or antiviral therapies, including, but not limited to, colitis, for example, pseudo-membranous colitis; antibiotic associated diarrhea; and infections due to Clostridium difficile (“C. difficile”), Clostridium perfringens (“C. perfringens”), Staphylococcus species, for example, methicillin-resistant Staphylococcus, or Enterococcus including Vancomycin-resistant enterococci.Type: ApplicationFiled: April 11, 2008Publication date: August 14, 2008Applicant: OPTIMER PHARMACEUTICALS, INC.Inventors: Yu-Hung Chiu, Tessie Mary Che, Alex Romero, Yoshi Ichikawa, Youe-Kong Shue
-
Publication number: 20080176927Abstract: The present invention is related to pharmaceutical compositions of one or more tiacumicins that exhibit improved stability, and methods of treatment using such formulations. The formulations contain one or more tiacumicins, such as difimicin, and one or more antioxidants, such as butylated hydroxytoluene, and, optionally, one or more pharmaceutically acceptable excipients.Type: ApplicationFiled: January 14, 2008Publication date: July 24, 2008Applicant: Optimer Pharmaceuticals, Inc.Inventors: Suketu Sanghvi, Mark Roach, Joseph F. Zhou, Eric Michael Mittleberg, Ping He
-
Patent number: 7378508Abstract: The invention relates to novel forms of compounds displaying broad spectrum antibiotic activity, especially crystalline polymorphic forms and amorphous forms of such compounds, compositions comprising such crystalline polymorphic forms and amorphous forms of such compounds, processes for manufacture and use thereof. The compounds and compositions of the invention are useful in the pharmaceutical industry, for example, in the treatment or prevention of diseases or disorders associated with the use of antibiotics, chemotherapies, or antiviral therapies, including, but not limited to, colitis, for example, pseudo-membranous colitis; antibiotic associated diarrhea; and infections due to Clostridium difficile (“C. difficile”), Clostridium perfringens (“C. perfringens”), Staphylococcus species, for example, methicillin-resistant Staphylococcus, or Enterococcus including Vancomycin-resistant enterococci.Type: GrantFiled: July 31, 2007Date of Patent: May 27, 2008Assignee: Optimer Pharmaceuticals, Inc.Inventors: Yu-Hung Chiu, Tessie Mary Che, Alex Romero, Yoshi Ichikawa, Youe-Kong Shue
-
Publication number: 20070197471Abstract: This invention relates to treating, preventing, and lessening the severity of conditions selected from the group consisting of osteoarthritis, rheumatoid arthritis, synovitis, subchondral bone edema, and cartilage degradation with administration of glycosidase inhibitors.Type: ApplicationFiled: January 20, 2005Publication date: August 23, 2007Applicants: Optimer Pharmaceuticals, Inc., The Scripps Research InstituteInventor: Yoshitaka Ichikawa
-
Publication number: 20070173462Abstract: This invention relates to the treatment or prevention of diseases associated with the use of antibiotics or cancer chemotherapies or antiviral therapies, such as colitis, pseudomembranous colitis, antibiotic associated diarrhea and infections due to C difficile, C. perfringens, Staphylococcus species including methicillin-resistant Staphylococcus aureus (MRSA) or Enterococcus including vancomycin-resistant enterococci (VRE) with Compound I.Type: ApplicationFiled: May 13, 2005Publication date: July 26, 2007Applicant: Optimer Pharmaceuticals, Inc.Inventors: Youe-Kong Shue, Farah Kondori Babakhari, Franklin Okumu, Pamela Suzanne Sears, Starr Louise Milller-Shangle, Robert Brian Walsh
-
Publication number: 20070105791Abstract: A method of treating a disease or disorder caused by the presence of a bacterium selected from the group consisting Clostridium species, Staphylococcus species, Enterococcus species and combinations thereof comprising administering to a patient in need an effective amount of a mixture, which comprises tiacumicin B, lipiarmycin A4, and at least one of other macrocyclic compounds:Type: ApplicationFiled: October 23, 2006Publication date: May 10, 2007Applicant: Optimer Pharmaceuticals, Inc.Inventors: Pamela Sears, Starr Louise Miller-Shangle, Robert Brian Walsh, Youe-Kong Shue, Farah Babakhani, Thomas Louie, Chiu Yu-Hung, Alex Romero, Sherwood Gorbach
-
Publication number: 20070082851Abstract: This invention relates to methods of treating, preventing, and lessening the severity of conditions or diseases selected from the group consisting of osteoarthritis (OA), rheumatoid arthritis, synovitis, subchondral bone edema, and cartilage degradation (“OA and related disorders”) with administration of an aminosugar derivative and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: November 23, 2004Publication date: April 12, 2007Applicants: Optimer Pharmaceuticals Inc., The Scripps Research InstituteInventor: Yoshitaka Ichikawa
-
Publication number: 20060257981Abstract: Methods, processes and materials for the production and recovery of Tiacumicins produced by culturing a microorganism belonging to the species Dactylosporangium aurantiacum subspecies hamdenensis having the ability to produce and accumulate one or more Tiacumicin in a nutrient medium comprising a carbon source, a nitrogen source, trace elements such as inorganic salts, and an adsorbent, wherein said nitrogen source comprises fish powder, and wherein said Tiacumicin is produced in a yield greater than about 50 mg/L broth.Type: ApplicationFiled: July 15, 2003Publication date: November 16, 2006Applicant: Optimer Pharmaceuticals, Inc.Inventors: Youe-Kong Shue, Chi-Jen Du, Ming-Hsi Chiou, Mei-Chiao Wu, Yuan-Ting Chen, Franklin Okumu, Jonathan Duffield